2025 Core Components & Current Recommended Dosing
- Fenbendazole 444 mg daily (two 1-g packets Panacur C or one 444 mg capsule) – most users now take 7 days/week
- Curcumin 600 mg/day (high-bioavailability, e.g., Theracurmin or with piperine)
- Vitamin E (succinate or γ-tocopherol preferred) 400–800 IU/day
- CBD Oil (full-spectrum) 25 mg/day ( sublingual)
- Common add-ons: Berberine, quercetin, milk thistle (liver support)
Note on original vs updated dosing: Joe originally used 222 mg for 3 days ON / 4 days OFF. He later increased to 444 mg daily and has publicly stated the higher dose is safe and preferred for most adults.
Mechanistic Rationale
- Fenbendazole → microtubule destabilisation → mitotic arrest & p53 activation
- Curcumin / Vitamin E → NF-κB, STAT3, COX-2 inhibition
- CBD → TRPV1 & PPAR-γ activation, anti-angiogenesis, apoptosis
Evidence Snapshot 2025
- Case reports & in-vitro / animal data; no RCTs
- Protocol publicised after Joe Tippens’ SCLC remission (2017)
- Thousands of new 2025 testimonials across private groups
Cycle / Monitoring
- Continuous; imaging q8–12 weeks
- Liver panel & CBC q4–6 weeks
Key Cautions
- Mild hepatotoxicity possible; rare neutropenia
- High-dose γ-tocopherol may thin blood — monitor with anticoagulants